Phase 3 Clinical Trials With Primary Completion Dates in June 2019
This is a list of Phase 3 trials with primary completion dates in June 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|AIMT||Aimmune Therapeutics, Inc.||2019-06-01||Phase 3||NCT02993107||PALISADE Follow-on Study (ARC004)|
|ALDX||Aldeyra Therapeutics, Inc.||2019-06-01||Phase 3||NCT03131154||SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.|
|ALKS||Alkermes plc||2019-06-01||Phase 3||NCT03093324||A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2|
|CCXI||ChemoCentryx, Inc.||2019-06-01||Phase 3||NCT02994927||A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis|
|DMPI||DelMar Pharmaceuticals, Inc.||2019-06-01||Phase 3||NCT03149575||VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM|
|ICLR||ICON plc||2019-06-01||Phase 3||NCT02586155||Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD|
|ITCI||Intra-Cellular Therapies Inc.||2019-06-01||Phase 3||NCT03249376||Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally|
|ITCI||Intra-Cellular Therapies Inc.||2019-06-01||Phase 3||NCT02600494||Clinical Trial Evaluating ITI-007 as a Monotherapy for the Treatment of Bipolar Depression|
|KMPH||KemPharm, Inc.||2019-06-01||Phase 3||NCT03460652||KP415 Open-Label Safety Study in Children (6-12 Years of Age) With ADHD|
|SLNO||Soleno Therapeutics, Inc.||2019-06-01||Phase 3||NCT03440814||A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome|
|TGTX||TG Therapeutics, Inc.||2019-06-01||Phase 3||NCT02301156||Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)|
|ZGNX||Zogenix, Inc.||2019-06-01||Phase 3||NCT02682927||A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome|